NTCP Inhibitor (Bulevirtide/Hepcludex)

About Hepatera

Hepatera is a clinical-stage biotech advancing a novel NTCP inhibitor for hepatitis B and D, with its lead program having achieved regulatory designations in Russia, the EU, and as a Breakthrough Therapy from the FDA. The company leverages a unique mechanism of action that blocks viral entry, demonstrating superiority over existing interferon-based therapies in clinical trials. Backed by Russian state initiatives and key European academic and industry partners, Hepatera is positioned to address a significant unmet need in viral hepatitis. Its primary candidate has treated over 550 patients in clinical studies and is progressing toward broader commercialization.

Therapeutic Areas